Voluntary announcement the first patient dosed in phase i clinical trial of Y225 for treatment of hemophilia a
Filed with HKEX · Stock code 2496 · · 2 pages · English
Wuhan YZY Biopharma Co., Ltd. on 6ix
Earlier from Wuhan YZY Biopharma
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Delay in despatch of circular in relation to (1) connected transaction in respect of the proposed issue of new domestic shares under Specific mandate; (2) application for Whitewash Waiver; and (3) proposed amendments to the articles of association
- Update on the qualification of joint company secretary and resignation of joint company secretary and change of process agent
- 2026 Interim report
- Poll results of the annual general meeting held on Monday, June 29, 2026
Follow Wuhan YZY Biopharma into a list and get an email when it puts out news.
Follow Wuhan YZY Biopharma